|1.||Sato, Hiroyuki: 1 article (06/2011)|
|2.||Arakawa, Tetsuo: 1 article (06/2011)|
|3.||Watanabe, Toshio: 1 article (06/2011)|
|4.||Fujiwara, Yasuhiro: 1 article (06/2011)|
|5.||Tominaga, Kazunari: 1 article (06/2011)|
|6.||Fujikawa, Yoshiko: 1 article (06/2011)|
|7.||Saito, Ichimonji: 1 article (11/2005)|
|8.||Kawasaki, Hironaka: 1 article (11/2005)|
|9.||Bamba, Tadao: 1 article (11/2005)|
|10.||Kamada, Takenobu: 1 article (11/2005)|
|1.||Duodenal Ulcer (Curling's Ulcer)
08/18/1986 - "This study demonstrated that enprostil is highly effective in the treatment of duodenal ulcer and has a favorable safety profile."
09/01/1989 - "These results indicate that enprostil 35 micrograms taken twice daily for four weeks is effective and safe for the treatment of prepyloric, pyloric channel, and duodenal ulcers."
08/18/1986 - "These results indicate that 35 micrograms of enprostil twice daily provides effective and safe therapy for patients with duodenal ulcer."
04/01/1987 - "The effects of bedtime 70 micrograms and twice daily 35 micrograms doses of enprostil on 24-hour intragastric acidity were investigated in nine duodenal ulcer patients in remission. "
01/01/1989 - "This study demonstrates the efficacy and safety of enprostil in the treatment of active duodenal ulcer at the dosage of 35 micrograms twice daily."
|2.||Stomach Ulcer (Gastric Ulcer)
08/18/1986 - "This study evaluated the efficacy of two dosage levels of enprostil in 129 patients with gastric ulcer disease. "
12/01/1990 - "In a randomly allocated, double-blind, endoscopically controlled study, 98 patients with gastric ulcers were treated with either (a synthetic prostaglandin of E2-like structure) enprostil 70 micrograms b.d. "
11/01/2005 - "In 43 hospitals 171 intention-to-treat (ITT) patients, diagnosed as having gastric ulcer by endoscopy, were randomly allocated to receive either enprostil 25microg b.i.d. "
07/01/1994 - "Additional gastric erosions and gastric ulcers developed in 16% of placebo patients and 4% of the enprostil patients. "
07/01/1994 - "Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil)."
01/01/1991 - "That finding, which is in keeping with the results of acute single-dose studies, suggests that stimulation of bicarbonate secretion by enprostil is not merely a transient phenomenon involved in the prevention of mucosal injury, but a lasting effect that may contribute to the ulcer-healing activity of the drug."
08/01/1986 - "Gastric mucosal binding studies with enprostil: a potent anti-ulcer prostaglandin."
01/01/2000 - "Enprostil significantly reduced both the area of damaged mucosa (including the ulcer area) and the macroscopic score after 3 days' treatment compared with control. "
07/01/1994 - "Complete mucosal healing of all erosions and ulcers at 9 wk occurred in 59% of enprostil-treated patients and in 10% of placebo-treated patients. "
07/01/1994 - "The ulcer healing rates were 14%, 57%, and 68% at 6 wk and 19%, 68%, and 74% at 9 wk for the groups receiving placebo, enprostil twice daily, and enprostil three times daily, respectively (p < 0.01). "
09/01/1989 - "Daytime pain was relieved more quickly in the enprostil group, while median time to relief of nighttime pain was essentially identical in both groups. "
11/01/1987 - "Moreover, enprostil has been shown to relieve daytime pain in a similar percentage of patients as do these H2-receptor antagonists, but night-time pain appears to respond less well to therapy with the prostaglandin. "
11/01/1987 - "Gastrointestinal symptoms-abdominal cramping and pain, flatulence, nausea and notably, diarrhoea-are the most frequently reported side effects during therapy with enprostil. "
10/01/1989 - "Relapse, defined as recurrent ulcer with or without pain, or erosions with pain, was significantly greater in patients on enprostil, the comparative rates at 3, 6 and 12 months were: enprostil 23, 31 and 36% ranitidine 6, 12 and 17% (P = 0.013; P = 0.03 and P = 0.03, respectively). "
04/11/1987 - "One hundred and forty two patients with duodenal ulcer who after a short term study had relief of pain and healed ulcers proved endoscopically were allocated at random to double blind maintenance treatment with enprostil (a synthetic dehydroprostaglandin E2) 35 micrograms or ranitidine 150 mg at bedtime for up to 12 months. "
|5.||Peptic Ulcer (Peptic Ulcers)
11/01/1987 - "Although the possible effects of enprostil on 'defensive' factors in peptic ulcer disease-which are thought to protect the mucosa-require much further clarification, some evidence obtained in man indicates that bicarbonate secretion is enhanced by enprostil. "
07/01/1986 - "Enprostil, an orally active prostaglandin E2 analog, is undergoing clinical trials in the treatment of peptic ulcer disease. "
08/01/1997 - "Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients."
01/01/1992 - "[The treatment of patients with duodenal peptic ulcer with a synthetic prostaglandin E2 analog (enprostil)]."
01/01/1991 - "[Synthetic analog of prostaglandin E2 (enprostil) in the treatment of peptic ulcer]."